tetano
Editor, Senior Moderator
Eur J Haematol
. 2023 Sep 22.
doi: 10.1111/ejh.14108. Online ahead of print. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study
Lars Christian Lund[SUP] 1 [/SUP], Martin Torp Rahbek[SUP] 1 [/SUP], Peter Brown[SUP] 2 [/SUP], Niels Obel[SUP] 3 [/SUP], Jesper Hallas[SUP] 1 [/SUP], Henrik Frederiksen[SUP] 4 5 [/SUP]
Affiliations
Objectives: We aimed to quantify the risk of death following a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals with haematological malignancies, stratified by virus variants and type of malignancy.
Methods: Using the Danish nationwide registries, we conducted a population-based cohort study among individuals who received a discharge diagnosis of haematological malignancies during the 5 years prior to testing positive for SARS-CoV-2 (February 2020-April 2023). All individuals were followed for 30 days after a positive test, and overall and time-stratified case fatality risks (CFR) were estimated.
Results: We identified 7154 individuals with a history of haematological malignancies who tested positive for SARS-CoV-2. Among these, we observed 223 deaths, yielding a CFR of 3.1%. The CFR was highest at the beginning of the pandemic (10%) and gradually declined to 1.9% during the period of Omicron BA1/BA2 predominance. The highest CFR was observed among individuals with acute leukaemia (CFR 6.2%, adjusted relative risk 1.95, 95% confidence interval 1.33-2.88) compared to individuals with lymphoma (CFR 3%).
Conclusions: We observed a reduction in the CFR over time, which may be attributed to new treatments, COVID-19 vaccination and the emergence of less aggressive variants.
Keywords: COVID-19; hematologic neoplasms; mortality.
. 2023 Sep 22.
doi: 10.1111/ejh.14108. Online ahead of print. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study
Lars Christian Lund[SUP] 1 [/SUP], Martin Torp Rahbek[SUP] 1 [/SUP], Peter Brown[SUP] 2 [/SUP], Niels Obel[SUP] 3 [/SUP], Jesper Hallas[SUP] 1 [/SUP], Henrik Frederiksen[SUP] 4 5 [/SUP]
Affiliations
- PMID: 37740535
- DOI: 10.1111/ejh.14108
Objectives: We aimed to quantify the risk of death following a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals with haematological malignancies, stratified by virus variants and type of malignancy.
Methods: Using the Danish nationwide registries, we conducted a population-based cohort study among individuals who received a discharge diagnosis of haematological malignancies during the 5 years prior to testing positive for SARS-CoV-2 (February 2020-April 2023). All individuals were followed for 30 days after a positive test, and overall and time-stratified case fatality risks (CFR) were estimated.
Results: We identified 7154 individuals with a history of haematological malignancies who tested positive for SARS-CoV-2. Among these, we observed 223 deaths, yielding a CFR of 3.1%. The CFR was highest at the beginning of the pandemic (10%) and gradually declined to 1.9% during the period of Omicron BA1/BA2 predominance. The highest CFR was observed among individuals with acute leukaemia (CFR 6.2%, adjusted relative risk 1.95, 95% confidence interval 1.33-2.88) compared to individuals with lymphoma (CFR 3%).
Conclusions: We observed a reduction in the CFR over time, which may be attributed to new treatments, COVID-19 vaccination and the emergence of less aggressive variants.
Keywords: COVID-19; hematologic neoplasms; mortality.